Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
3(100.0%)
3Total
Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06451770Phase 1Recruiting

Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia

Role: lead

NCT06112327Enrolling By Invitation

Long-term Follow-up of Participants Dosed With an Investigational Gene Editing Therapy for Cardiovascular Disease

Role: lead

NCT06164730Phase 1Recruiting

A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease

Role: lead

NCT05398029Phase 1Completed

A Study of VERVE-101 in Patients With Familial Hypercholesterolemia and Cardiovascular Disease

Role: lead

All 4 trials loaded